ADJUVANT DURVALUMAB IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF CANCER

摘要

The disclosure generally relates to methods for treating cancer in a patient using durvalumab in combination with chemotherapy based on the patient's minimal residual status. Specifically, the disclosure relates to preventing or treating a recurrent tumor in a patient, wherein the patient is minimal residual disease-positive (MRD+), using durvalumab and chemotherapy.